A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
BeOne Medicines
Gilead Sciences
Seagen Inc.
Hoffmann-La Roche
AstraZeneca
Bristol-Myers Squibb
Thomas Jefferson University
Fudan University
Gilead Sciences
BeOne Medicines
University Health Network, Toronto
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
CSPC Megalith Biopharmaceutical Co.,Ltd.
Mayo Clinic
Sun Yat-sen University
Weill Medical College of Cornell University
Bristol-Myers Squibb
Genfleet Therapeutics (Shanghai) Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Genelux Corporation
BeiGene
Mirati Therapeutics Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Iovance Biotherapeutics, Inc.
Ohio State University Comprehensive Cancer Center
Shanghai Chest Hospital
Fundación GECP
Merck Sharp & Dohme LLC
Tianjin Medical University Cancer Institute and Hospital
EpicentRx, Inc.
M.D. Anderson Cancer Center
ImmunityBio, Inc.
Goethe University
AstraZeneca
Sichuan University
Hunan Province Tumor Hospital
Spanish Lung Cancer Group
Merck Sharp & Dohme LLC
BeBetter Med Inc
Tang-Du Hospital
Hunan Province Tumor Hospital
Canadian Cancer Trials Group
EMD Serono
Sun Yat-sen University
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Barbara Ann Karmanos Cancer Institute
Nanfang Hospital, Southern Medical University